The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Risk of skeletal-related events (SREs) in patients with prostate cancer (PC) and newly diagnosed metastases to bone.
Andrew Glass
Research Funding - Amgen
Lois Lamerato
Research Funding - Amgen
John Edelsberg
Research Funding - Amgen
Kathryn E. Richert-Boe
Research Funding - Amgen
Charu Taneja
Research Funding - Amgen
Greg G. Wolff
Research Funding - Amgen
Natalie Czapski
Research Funding - Amgen
Karen Chung
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Akshara Richhariya
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Gerry Oster
Research Funding - Amgen